Danijela D MaksimoviÄ**‡**vanić

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6226862/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Borcalein: a Carboraneâ€Based Analogue of Baicalein with 12â€Lipoxygenaseâ€Independent Toxicity. ChemMedChem, 2022, 17, .	3.2	8
2	Combined Action of Hyper-Harmonized Hydroxylated Fullerene Water Complex and Hyperpolarized Light Leads to Melanoma Cell Reprogramming In Vitro. Nanomaterials, 2022, 12, 1331.	4.1	7
3	Carboranyl Analogues of Mefenamic Acid and Their Biological Evaluation. ACS Omega, 2022, 7, 24282-24291.	3.5	13
4	Carborane-Based Analog of Rev-5901 Attenuates Growth of Colon Carcinoma In Vivo. Molecules, 2022, 27, 4503.	3.8	3
5	The Middle Part of the Plucked Hair Follicle Outer Root Sheath Is Identified as an Area Rich in Lineage-Specific Stem Cell Markers. Biomolecules, 2021, 11, 154.	4.0	11
6	Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand. Molecules, 2021, 26, 1860.	3.8	2
7	Antitumor potential of cisplatin loaded into SBA-15 mesoporous silica nanoparticles against B16F1 melanoma cells: in vitro and in vivo studies. Journal of Inorganic Biochemistry, 2021, 217, 111383.	3.5	12
8	Development of genistein-loaded gold nanoparticles and their antitumor potential against prostate cancer cell lines. Materials Science and Engineering C, 2021, 124, 112078.	7.3	31
9	Modulation of Î ³ -Secretase Activity by a Carborane-Based Flurbiprofen Analogue. Molecules, 2021, 26, 2843.	3.8	10
10	Ruthenacarborane and Quinoline: A Promising Combination for the Treatment of Brain Tumors. Molecules, 2021, 26, 3801.	3.8	4
11	A Comparative Analysis of the In Vitro Anticancer Activity of Iridium(III) {η5-C5Me4R} Complexes with Variable R Groups. International Journal of Molecular Sciences, 2021, 22, 7422.	4.1	4
12	The Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors. Antioxidants, 2020, 9, 374.	5.1	72
13	Quinolineâ€Conjugated Ruthenacarboranes: Toward Hybrid Drugs with a Dual Mode of Action. ChemMedChem, 2019, 14, 2061-2074.	3.2	9
14	2,2′â€Bipyridineâ€Modified Tamoxifen: A Versatile Vector for Molybdacarboranes. ChemMedChem, 2019, 14, 2075-2083.	3.2	13
15	Synthetic Tubulysin Derivative, Tubugi-1, Against Invasive Melanoma Cells: The Cell Death Triangle. Anticancer Research, 2019, 39, 5403-5415.	1.1	2
16	Carboranyl Analogues of Ketoprofen with Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines. ACS Omega, 2019, 4, 8824-8833.	3.5	11
17	The synthetic tubulysin derivative, tubugi-1, improves the innate immune response by macrophage polarization in addition to its direct cytotoxic effects in a murine melanoma model. Experimental Cell Research, 2019, 380, 159-170.	2.6	7
18	Senescence as a main mechanism of Ritonavir and Ritonavirâ€NO action against melanoma. Molecular Carcinogenesis, 2019, 58, 1362-1375.	2.7	18

#	Article	IF	CITATIONS
19	The hop-derived prenylflavonoid isoxanthohumol inhibits the formation of lung metastasis in B16-F10 murine melanoma model. Food and Chemical Toxicology, 2019, 129, 257-268.	3.6	14
20	Impact of the mesoporous silica SBA-15 functionalization on the mode of action of Ph3Sn(CH2)6OH. Materials Science and Engineering C, 2019, 100, 315-322.	7.3	12
21	Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo. Investigational New Drugs, 2019, 37, 1014-1028.	2.6	41
22	The interaction between SBA-15 derivative loaded with Ph3Sn(CH2)6OH and human melanoma A375 cell line: uptake and stem phenotype loss. Journal of Biological Inorganic Chemistry, 2019, 24, 223-234.	2.6	17
23	Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines. ChemMedChem, 2019, 14, 315-321.	3.2	20
24	Carboraneâ€Based Analogues of 5‣ipoxygenase Inhibitors Coâ€inhibit Heat Shock Protein 90 in HCT116 Cells. ChemMedChem, 2019, 14, 255-261.	3.2	18
25	Prostate cancer metastasis and soy isoflavones: a dogfight over a bone. EXCLI Journal, 2019, 18, 106-126.	0.7	4
26	Naturally occurring compounds in differentiation based therapy of cancer. Biotechnology Advances, 2018, 36, 1622-1632.	11.7	31
27	Delivery of [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study. Journal of Inorganic Biochemistry, 2018, 180, 155-162.	3.5	14
28	Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells. Molecules, 2018, 23, 2463.	3.8	36
29	Drug Delivery System for Emodin Based on Mesoporous Silica SBA-15. Nanomaterials, 2018, 8, 322.	4.1	25
30	Aloe emodin: From antito pro-tumor action. Hrana I Ishrana, 2018, 59, 59-67.	0.2	2
31	CarbORevâ€5901: The First Carboraneâ€Based Inhibitor of the 5â€Lipoxygenase Pathway. ChemMedChem, 2017, 12, 1081-1086.	3.2	15
32	Antiproliferative activity of (η ⁶ -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines. Dalton Transactions, 2017, 46, 12067-12080.	3.3	16
33	HIVâ€protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NOâ€hybridized derivatives?. International Journal of Cancer, 2017, 140, 1713-1726.	5.1	63
34	Alpha-1-Antitrypsin Antagonizes Cisplatin-Induced Cytotoxicity in Prostate Cancer (PC3) and Melanoma Cancer (A375) Cell Lines. Pathology and Oncology Research, 2017, 23, 335-343.	1.9	4
35	Ti-SLActive and TiZr-SLActive Dental Implant Surfaces Promote Fast Osteoblast Differentiation. Coatings, 2017, 7, 102.	2.6	9
36	(18-Crown-6)potassium(I) Trichlorido[28-acetyl-3-(tris-(hydroxylmethyl)amino-ethane)betulinic ester-κN]platinum(II): Synthesis and In Vitro Antitumor Activity. Inorganics, 2017, 5, 56.	2.7	2

#	Article	IF	CITATIONS
37	Antiproliferative activity of ruthenium(<scp>ii</scp>) arene complexes with mono- and bidentate pyridine-based ligands. Dalton Transactions, 2016, 45, 13114-13125.	3.3	34
38	Evaluation of functionalized mesoporous silica SBA-15 as a carrier system for Ph ₃ Sn(CH ₂) ₃ OH against the A2780 ovarian carcinoma cell line. Dalton Transactions, 2016, 45, 18984-18993.	3.3	27
39	Versatile antitumor potential of isoxanthohumol: Enhancement of paclitaxel activity in vivo. Pharmacological Research, 2016, 105, 62-73.	7.1	58
40	Anticancer Activity of Organogallium(III) Complexes in Colon Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 359-364.	1.7	10
41	Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 1455-1460.	1.7	8
42	Binuclear dichlorido(η ⁶ â€ <i>p</i> â€cymene)ruthenium(II) complexes with bis(nicotinate)―and bis(isonicotinate)â€polyethylene glycol ester ligands. Applied Organometallic Chemistry, 2015, 29, 20-25.	3.5	8
43	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. Leukemia Research, 2015, 39, 1088-1095.	0.8	25
44	Improved in vitro antitumor potential of (O,O′-Diisobutyl-ethylenediamine-N,N′-di-3-propionate)tetrachloridoplatinum(IV) complex under normoxic and hypoxic conditions. European Journal of Pharmacology, 2015, 760, 136-144.	3.5	7
45	Ruthenium(II) p-cymene complex bearing 2,2′-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response. Journal of Inorganic Biochemistry, 2015, 153, 315-321.	3.5	27
46	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget, 2014, 5, 4603-4650.	1.8	231
47	A Key Role of Autophagy in Osteoblast Differentiation on Titanium-Based Dental Implants. Cells Tissues Organs, 2014, 200, 265-277.	2.3	37
48	Organotin(IV)‣oaded Mesoporous Silica as a Biocompatible Strategy in Cancer Treatment. Angewandte Chemie - International Edition, 2014, 53, 5982-5987.	13.8	82
49	Synthesis, X-ray structure and strong inÂvitro cytotoxicity of novel organoruthenium complexes. Journal of Organometallic Chemistry, 2014, 749, 142-149.	1.8	7
50	Study of the anticancer properties of methyl- and phenyl-substituted carbon- and silicon-bridged ansa-titanocene complexes. Journal of Organometallic Chemistry, 2014, 751, 361-367.	1.8	10
51	Undecylprodigiosin conjugated monodisperse gold nanoparticles efficiently cause apoptosis in colon cancer cells in vitro. Journal of Materials Chemistry B, 2014, 2, 3271-3281.	5.8	10
52	Alkenyl-substituted titanocene dichloride complexes: Stability studies, binding and cytotoxicity. Journal of Organometallic Chemistry, 2014, 769, 46-57.	1.8	6
53	Anticancer Potential of (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing ΰ <i>P</i> and ΰ <i>P</i> ,ΰ <i>S</i> oordinated Ph ₂ PCH ₂ CH ₂ CH ₂ S(O) _{<i>x</i>} Ph (<i>x</i>)=0â€*2) Ligands, ChemMedChem, 2014, 9, 1586,1593	3.2	10
54	Extracellular iron diminishes anticancer effects of vitamin C: An in vitro study. Scientific Reports, 2014, 4, 5955.	3.3	50

#	Article	IF	CITATIONS
55	Membrane Fluidity, Invasiveness and Dynamic Phenotype of Metastatic Prostate Cancer Cells after Treatment with Soy Isoflavones. Journal of Membrane Biology, 2013, 246, 307-314.	2.1	22
56	Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph2PCH2S(O)xPh (xÂ=Â0–2) ligands. European Journal of Medicinal Chemistry, 2013, 69, 216-222.	5.5	24
57	Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2013, 259, 55-65.	2.3	9
58	No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST ĆELIJA NESITNOĆELIJSKOG KARCINOMA PLUĆA RAZLIČITE OSETUIVOSTI NA DOKSORUBICIN. Journal of Med Biochemistry, 2013, 32, 406-416.	ical	2
59	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. Cell Cycle, 2012, 11, 1174-1182.	2.6	14
60	On the Discovery, Biological Effects, and Use of Cisplatin and Metallocenes in Anticancer Chemotherapy. Bioinorganic Chemistry and Applications, 2012, 2012, 1-14.	4.1	115
61	Metals in Medicine. Bioinorganic Chemistry and Applications, 2012, 2012, 1-2.	4.1	4
62	Melanoma tumor inhibition by tetrachlorido(O,O′-dibutyl-ethylenediamine-N,N′-di-3-propionate)platinum(iv) complex: in vitro and in vivo investigations. Metallomics, 2012, 4, 1155.	2.4	15
63	Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells. Molecular Pharmacology, 2012, 82, 700-710.	2.3	28
64	Platinum(ii/iv) complexes containing ethylenediamine-N,N′-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells. Metallomics, 2012, 4, 979.	2.4	35
65	Cell-type dependent response of melanoma cells to aloe emodin. Food and Chemical Toxicology, 2012, 50, 3181-3189.	3.6	37
66	Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. Oncology Reports, 2012, 28, 682-688.	2.6	18
67	Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. Current Pharmaceutical Design, 2012, 18, 1784-1795.	1.9	39
68	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	1.8	279
69	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response Oncotarget, 2012, 3, 954-987.	1.8	244
70	Resistance to TRAIL and how to surmount it. Immunologic Research, 2012, 52, 157-168.	2.9	48
71	Novel methylene modified cyclohexyl ethylenediamine-N,N′-diacetate ligands and their platinum(IV) complexes. Influence on biological activity. Journal of Inorganic Biochemistry, 2012, 109, 40-48.	3.5	29
72	Advances in Targeting Signal Transduction Pathways. Oncotarget, 2012, 3, 1505-1521.	1.8	41

#	Article	IF	CITATIONS
73	In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle, 2011, 10, 492-499.	2.6	47
74	Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. Journal of Cellular Physiology, 2011, 226, 1803-1812.	4.1	30
75	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. Journal of Cellular Physiology, 2011, 226, 2762-2781.	4.1	147
76	Multiple antimelanoma potential of dry olive leaf extract. International Journal of Cancer, 2011, 128, 1955-1965.	5.1	48
77	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging, 2011, 3, 192-222.	3.1	520
78	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget, 2011, 2, 135-164.	1.8	509
79	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. Free Radical Biology and Medicine, 2010, 48, 1090-1099.	2.9	10
80	(S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid–Nitric Oxide (GIT-27NO) – New Dress for Nitric Oxide Mission. , 2010, , 443-457.		0
81	The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. European Journal of Pharmacology, 2009, 615, 228-233.	3.5	15
82	The antitumor properties of a nontoxic, nitric oxide–modified version of saquinavir are independent of Akt. Molecular Cancer Therapeutics, 2009, 8, 1169-1178.	4.1	38
83	Anticancer Properties ofGanoderma LucidumMethanol Extracts In Vitro and In Vivo. Nutrition and Cancer, 2009, 61, 696-707.	2.0	67
84	Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. Journal of Cellular Physiology, 2008, 215, 665-675.	4.1	76
85	Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid–nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide - Biology and Chemistry, 2008, 19, 177-183.	2.7	26
86	Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: In vitro and in vivo study. Food and Chemical Toxicology, 2008, 46, 1825-1833.	3.6	63
87	Anticancer properties of the novel nitric oxide-donating compound (<i>S,R</i>)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide <i>in vitro</i> and <i>in vivo</i> . Molecular Cancer Therapeutics, 2008, 7, 510-520.	4.1	68
88	Control of the of the final stage of immune-mediated diabetes by ISO-1, an antagonist of macrophage migration inhibitory factor. Archives of Biological Sciences, 2008, 60, 389-401.	0.5	9
89	A Potent Immunomodulatory Compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxasole Acetic Acid, Prevents Spontaneous and Accelerated Forms of Autoimmune Diabetes in NOD Mice and Inhibits the Immunoinflammatory Diabetes Induced by Multiple Low Doses of Streptozotocin in CBA/H Mice.	2.5	32
90	Aloe emodin inhibits the cytotoxic action of tumor necrosis factor. European Journal of Pharmacology, 2007, 568, 248-259.	3.5	38

#	Article	IF	CITATIONS
91	Strain difference in susceptibility to experimental autoimmune encephalomyelitis between Albino Oxford and Dark Agouti rats correlates with disparity in production of IL-17, but not nitric oxide. Journal of Neuroscience Research, 2006, 84, 379-388.	2.9	49
92	Anti-glioma action of aloe emodin: the role of ERK inhibition. Cellular and Molecular Life Sciences, 2005, 62, 589-598.	5.4	85
93	Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin. Cellular and Molecular Life Sciences, 2005, 62, 1275-1282.	5.4	59
94	Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. Cellular and Molecular Life Sciences, 2005, 62, 2658-2668.	5.4	63
95	Critical Role of Macrophage Migration Inhibitory Factor Activity in Experimental Autoimmune Diabetes. Endocrinology, 2005, 146, 2942-2951.	2.8	115
96	Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. Journal of Autoimmunity, 2004, 22, 267-276.	6.5	23
97	Inhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue. Transplantation Proceedings, 2002, 34, 2955-2957.	0.6	7
98	Downregulation of apoptosis in the target tissue prevents low-dose streptozotocin-induced autoimmune diabetes. Molecular Immunology, 2002, 38, 941-946.	2.2	27
99	Down-regulation of experimental allergic encephalomyelitis in DA rats by tiazofurin. Journal of Neuroimmunology, 2002, 130, 66-77.	2.3	16
100	Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil. Clinical and Experimental Immunology, 2002, 129, 214-223.	2.6	25
101	Nitric oxide metabolites and interleukin-6 in cerebrospinal fluid from multiple sclerosis patients. European Journal of Neurology, 2002, 9, 413-418.	3.3	24
102	Antidiabetogenic Effect of Pentoxifylline is Associated with Systemic and Target Tissue Modulation of Cytokines and Nitric Oxide Production. Journal of Autoimmunity, 2001, 16, 47-58.	6.5	39
103	Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation with disease activity. Multiple Sclerosis Journal, 2001, 7, 19-22.	3.0	9
104	Differential regulation of nitric oxide production by increase of intracellular cAMP in murine primary fibroblasts and L929 fibrosarcoma cell line. Immunology Letters, 2000, 71, 149-155.	2.5	15
105	Cyclosporin A Suppresses the Induction of Nitric Oxide Synthesis in Interferon-gamma-Treated L929 Fibroblasts. Scandinavian Journal of Immunology, 1999, 49, 126-130.	2.7	14